Modified Cancer Peptide Antigens as Self-Adjuvanting Vaccine Candidates
Pam2Cys-modified cancer-testis antigen peptides demonstrated self-adjuvanting properties in vivo, representing a simplified peptide vaccine approach for cancer immunotherapy.
Quick Facts
What This Study Found
Pam2Cys-modified cancer-testis antigen peptides demonstrated self-adjuvanting properties in vivo, representing a simplified peptide vaccine approach for cancer immunotherapy.
Key Numbers
Two cancer-testis antigens tested with Pam2Cys modification in mice for immune response generation.
How They Did This
Study methodology detailed in the full publication.
Why This Research Matters
Relevant to the expanding applications of peptide-based therapies in medicine.
The Bigger Picture
Contributes to the growing body of evidence for peptide therapeutics across medical specialties.
What This Study Doesn't Tell Us
Limitations discussed in the full publication.
Questions This Raises
- ?What are the long-term implications?
- ?How do results compare to existing evidence?
- ?What research is needed next?
Trust & Context
- Key Stat:
- Key finding Pam2Cys-modified cancer-testis antigen peptides demonstrated self-adjuvanting properties in vivo, re
- Evidence Grade:
- Evidence level based on study design.
- Study Age:
- Published in 2025.
- Original Title:
- In Vivo Evaluation of Pam2Cys-Modified Cancer-Testis Antigens as Potential Self-Adjuvanting Cancer Vaccines.
- Published In:
- Journal of peptide science : an official publication of the European Peptide Society, 31(6), e70022 (2025)
- Authors:
- Aljohani, Salwa, Edmonds, Alex G, Castelletto, Valeria(2), Seitsonen, Jani, Hamley, Ian W, Symonds, Peter, Brentville, Victoria A, Durrant, Lindy G, Mitchell, Nicholas J
- Database ID:
- RPEP-09869
Evidence Hierarchy
Frequently Asked Questions
What does this mean for patients?
Pam2Cys-modified cancer-testis antigen peptides demonstrated self-adjuvanting properties in vivo, representing a simplified peptide vaccine approach for cancer immunotherapy.
How reliable is this?
Consult the full publication and healthcare provider.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09869APA
Aljohani, Salwa; Edmonds, Alex G; Castelletto, Valeria; Seitsonen, Jani; Hamley, Ian W; Symonds, Peter; Brentville, Victoria A; Durrant, Lindy G; Mitchell, Nicholas J. (2025). In Vivo Evaluation of Pam2Cys-Modified Cancer-Testis Antigens as Potential Self-Adjuvanting Cancer Vaccines.. Journal of peptide science : an official publication of the European Peptide Society, 31(6), e70022. https://doi.org/10.1002/psc.70022
MLA
Aljohani, Salwa, et al. "In Vivo Evaluation of Pam2Cys-Modified Cancer-Testis Antigens as Potential Self-Adjuvanting Cancer Vaccines.." Journal of peptide science : an official publication of the European Peptide Society, 2025. https://doi.org/10.1002/psc.70022
RethinkPeptides
RethinkPeptides Research Database. "In Vivo Evaluation of Pam2Cys-Modified Cancer-Testis Antigen..." RPEP-09869. Retrieved from https://rethinkpeptides.com/research/aljohani-2025-in-vivo-evaluation-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.